TY  - JOUR 
AU  - Casado, L. F.
AU  - Garcia-Gutierrez, J. V.
AU  - Massague, I.
AU  - Giraldo, P.
AU  - Pérez Encinas, Manuel Mateo
AU  - de Paz, R.
AU  - Martinez-Lopez, J.
AU  - Bautista, G.
AU  - Osorio, S.
AU  - Requena, M. J.
AU  - Palomera, L.
AU  - Penarrubia, M. J.
AU  - Calle, C.
AU  - Hernandez-Rivas, J. A.
AU  - Burgaleta, C.
AU  - Maestro, B.
AU  - Garcia-Ormena, N.
AU  - Steegmann, J. L.
PY  - 2015
SN  - 2045-7634
UR  - http://hdl.handle.net/20.500.11940/2944
AB  - [EN] Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 months of...
LA  - eng
TI  - Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
DO  - 10.1002/cam4.440
T2  - Cancer Medicine
M2  - 995
VL  - 4
ER  -